Novel insights in ICU-acquired respiratory muscle dysfunction: implications for clinical care.
This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency medicine 2017. Other selected articles can be found online at http://ccforum.com/series/annualupdate2017 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901 .
VU University Medical Center, Department of Intensive Care Medicine, 1007 MB, Amsterdam, Netherlands.
Annemijn H
AH
Jonkman
Radboudumc, Department of Anesthesiology, Nijmegen, Netherlands.
Diana
D
Jansen
VU University Medical Center, Department of Intensive Care Medicine, 1007 MB, Amsterdam, Netherlands. l.heunks@vumc.nl.
Leo M A
LM
Heunks
D058109:Airway Management / Q000009:adverse effects*; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006835:Hydrazones / Q000494:pharmacology / Q000627:therapeutic use; D007362:Intensive Care Units / Q000458:organization & administration; D007902:Length of Stay / Q000706:statistics & numerical data*; D009133:Muscular Atrophy / Q000209:etiology; D011724:Pyridazines / Q000494:pharmacology / Q000627:therapeutic use; D012132:Respiratory Muscles / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D000077464:Simendan; D045165:Testosterone Congeners / Q000494:pharmacology / Q000627:therapeutic use
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D045165:Testosterone Congeners; D000077464:Simendan